The Global Health Body Sounds Concern Over Severe Shortage of Obesity Medications
Fewer than a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it publishes its first guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidelines recognises that obesity is a lifelong illness that can be addressed with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to widespread availability to the injections that can assist patients in reducing substantial weight, explains the organization.
GLP-1 Therapy Scarcity
Even under the present most optimistic case, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation calls on countries and companies to expand availability, by approaches like patent sharing.
The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Function
GLP-1 drugs replicate a biological compound to slow digestion, curb appetite and boost feelings of fullness so people eat less.
Individuals typically begin shedding pounds after several weeks of commencing the once-weekly jabs.
Evidence indicates users may put most of the weight back on after a year of stopping the medication, as their typical hunger resume.
To be above a healthy weight raises your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
